Examples of 'rofecoxib' in a sentence
Meaning of "rofecoxib"
Rofecoxib (noun) - A nonsteroidal anti-inflammatory drug that has been withdrawn from the market due to safety concerns
Show more definitions
- A COX-2 inhibitor C₁₇H₁₄O₄S (trademark Vioxx) used to relieve the signs and symptoms of osteoarthritis and rheumatoid arthritis, to manage acute pain in adults, and to treat primary dysmenorrhea but withdrawn from sale by the manufacturer because of its link to cardiovascular events (as heart attack and stroke).
How to use "rofecoxib" in a sentence
Basic
Advanced
rofecoxib
Celecoxib and rofecoxib are listed as preferred diphenyl heterocycle derivatives.
Observational studies also questioned the cardiovascular safety of rofecoxib.
Rofecoxib is one example.
The elevated risk began during the second month on rofecoxib.
Rofecoxib was one of the most used drugs to be withdrawn from the market.
This mechanism may be involved in the adverse cardiovascular effects of rofecoxib.
Naproxen or rofecoxib.
An additional aim of the study was to further evaluate the cardiovascular safety of rofecoxib.
The Rofecoxib has a diaryl heterocyclic structure with a central furanone ring.
Six studies showed no increased risk associated with rofecoxib use.
This led to the withdrawal of rofecoxib and valdecoxib, and warnings on others.
A statistically significant increase in the incidence of myocardial infarctions was observed in patients on rofecoxib.
Rofecoxib causes a selective inhibition of the activity of cyclooxygenase-2 in the two groups of subjects.
Scientific studies conducted in humans who volunteer to test the effectiveness and safety of rofecoxib.
The new data provided on rofecoxib by the APPROVe clinical study, which revealed a risk of.
See also
Health professionals are requested to report any suspect serious adverse reactions associated with rofecoxib.
Ibuprofen, celecoxib, and rofecoxib are particularly preferred NSAIDs in the method according to the invention.
Several very large observational studies have also found elevated risk of heart attack from rofecoxib.
Rofecoxib % If the sponsor chooses to apply for renewed.
Precautions for Rofecoxib.
In a few tests, Rofecoxib was administered as the final preparation Vioxx and Celecoxib as Celebrex.
On that occasion, an antibiotic ciprofloxacin and an anti-inflammatory rofecoxib were started.
Chemicals - Commercial formulations of rofecoxib tablets and celecoxib capsules were used.
Also the metabolism of caf-feine was impaired by rofecoxib.
The efficacy studies ' with rofecoxib in osteoarthritis were 6 weeks in duration.
Examples of useful Cox-II inhibitors include rofecoxib and celecoxib.
Rofecoxib ( Vioxx ) was removed from a market that was general.
However, they did not find any elevated cardiovascular risk due to rofecoxib.
Celecoxib and rofecoxib show anti-inflammatory potency comparable to conventional NSAIDs without COX-2 selectivity.
Examples of suitable diaryl substituted pyrazoles for use in the compositions include celecoxib, rofecoxib.
However, ibuprofen, celecoxib, rofecoxib and other CoxII inhibitors can also be used as the NSAID.
Moreover, overall and cardiovascular mortality rates were similar between the rofecoxib and placebo populations.
The effect of the COX-2 inhibitors rofecoxib and celecoxib on PGE2 levels was also analysed.
Notwithstanding these recommendations, Merck has not returned rofecoxib to the market.
Rofecoxib Use type cyclooxygenase ( COX-2 ) inhibitor . Nonsteroidal antiinflammatory drugs used to relieve symptoms of osteoarthritis.
Examples of COXIB inhibitors include but are not limited to, rofecoxib and celecoxib.
Vioxx, rofecoxib tablets [ product monograph ].
Subject: Withdrawal of the drug rofecoxib.
Each ml contained 7 mg rofecoxib and 6.4 mg strontium in the form of strontium acetate.
Compounds inhibiting COX 2 specifically may be Coxib derivatives such as Celecoxib or Rofecoxib.
When evaluating the rofecoxib doses employed, there was no significant difference between 25 mg / day and 50 mg / day.
Worldwide, over 80 million people were prescribed rofecoxib at some time.
The release of rofecoxib begins shortly after administration and end about 14-18 hours after administration.
The relative risk of myocardial infarction between naproxen and rofecoxib was 0.2.
Rofecoxib was found to be a mechanism-based inhibitor of CYP1A2.
Examples of Cox-II inhibitors include, but are not limited to, rofecoxib and celecoxib.
The COX-2 inhibitor rofecoxib caused decreased wall thickness and MPO activity at day 10.
In still another embodiment, the cyclooxygenase-2 inhibitor is Rofecoxib.
In vitro, fluvoxamine, tolfenamic acid, mefenamic acid and rofecoxib potently in-hibited CYP1A2.
The use as claimed in claim 8 wherein said COX-2 inhibitor is rofecoxib.
